食管鳞癌组织中TAZ和Lats2的表达及其临床意义

目的 探讨TAZ、Lats2在食管鳞癌组织中的表达情况，并分析其与临床病理特征及预后的关系。方法MaxVision免疫组织化学法检测145例食管鳞癌组织和39例癌旁组织中TAZ与Lats2的表达，并分析两者表达与临床病理特征和预后的关系。结果TAZ在食管鳞癌组织与癌旁组织中的高表达率分别为58.6％（85／145）和38.5％（15／39），差异有统计学意义（P＜0.05），且TAZ的表达与肿瘤浸润深度、淋巴结转移、组织学分级、肿瘤直径及pTNM分期有关（P＜0.05）。Lats2在食管鳞癌组织中的高表达率为45.5％（66／145），低于癌旁组织的64.1％（25／39），差异有统计学意义（P＜0.05），且Lats2的表达与肿瘤浸润深度、淋巴结转移及pTNM分期有关（P＜0.05）。TAZ与Lats2在食管鳞癌组织中的表达呈负相关（r=-0.272，P=0.001）。TAZ高表达者的中位总生存时间（OS）和无进展生存时间（PFS）分别为30个月和20个月，均低于低表达者的59个月和57个月（P均＜0.001）；Lats2高表达者的中位OS和PFS分别为42个月和33个月，均高于低表达者的32个月和18个月（P=0.035，P=0.019）。结论 TAZ、Lats2可能与食管鳞癌的发生、发展有关，对两者的检测可能对指导食管鳞癌的治疗及预后评估有重要意义。

Expression of TAZ and Lats2 in esophageal squamous cell carcinoma and their clinical significance

Objective To explore the expression of TAZ and Lats2 in esophageal squamous cell carcinoma( ESCC) , and the correlation of their expression with clinicopathological features and prognosis. Methods TAZ and Lats2 expression were determined by MaxVision immunohistochemical method in 145 ESCC tissues and 39 adjacent normal tissues, and their correlation with clinicopatholog-ical features were analyzed. Overall survival( OS) and progression-free survival( PFS) were further investigated. Results The high ex-pression rate of TAZ in ESCC tissues and adjacent normal tissues was 58. 6%( 85/145) and 38. 5%( 15/39) with significant difference (P<0. 05). TAZ expression level in tumor tissues was correlated with depth of invasion, lymph node status, tumor differentiation, tumor size and pTNM stages( P<0. 05) . The high expression rate of Lats2 in ESCC tissues and adjacent normal tissues was 45. 5%( 66/145) and 64. 1%(25/39) with significant difference(P<0. 05). Lats2 expression level in tumor tissues was correlated with depth of in-vasion, lymph node status and pTNM stages( P<0. 05) . In ESCC tissues, the expression of TAZ and Lats2 showed negative correlation ( r=-0. 272, P=0. 001) . The median OS and PFS of patients with high TAZ expression was 30 months and 20 months, lower than 59 months and 57 months of patients with low TAZ expression( P<0. 001) . The median OS and PFS of patients with high Lats2 expression was 42 months and 33 months, higher than 32 months and 18 months of patients with low Lats2 expression(P=0. 035, P=0. 019). Conclusion The expression of TAZ and Lats2 were bound up with the occurrence and progress of ESCC, and it may account for the e-valuation and the treatment of ESCC.